Literature DB >> 27453251

Molecular Analysis of BMPR2, TBX4, and KCNK3 and Genotype-Phenotype Correlations in Spanish Patients and Families With Idiopathic and Hereditary Pulmonary Arterial Hypertension.

Paula Navas1, Jair Tenorio2, Carlos Andrés Quezada1, Elvira Barrios3, Gema Gordo2, Pedro Arias2, Manuel López Meseguer4, Alejandro Santos-Lozano5, Julian Palomino Doza6, Pablo Lapunzina2, Pilar Escribano Subías7.   

Abstract

INTRODUCTION AND
OBJECTIVES: Recent advances in genetics have led to the discovery of new genes associated with pulmonary arterial hypertension, such as TBX4 and KCNK3. The phenotype and prognosis associated with these new genes have been scarcely described and their role in the Spanish population is unknown. The aim of this study was to characterize the genetics of a Spanish cohort of patients with idiopathic and hereditary pulmonary arterial hypertension and to describe the phenotype and prognostic factors associated with BMPR2 and the new genes (KCNK3 and TBX4).
METHODS: A total of 165 adult patients were screened for BMPR2, KCNK3, and TBX4 mutations, 143 with idiopathic pulmonary arterial hypertension and 22 with hereditary pulmonary arterial hypertension. Baseline characteristics and survival were compared among the different subgroups and predictors of poor outcomes were analyzed. We also performed family screening.
RESULTS: The genetic study identified a possibly associated mutation in 11.10% of the idiopathic cases (n = 16) and in 68.18% of the hereditary cases (n = 15). There were 19 mutations in BMPR2, 4 in TBX4, and 3 in KCNK3. The forms associated with TBX4 showed the highest survival rate (P < .01). Advanced functional class at diagnosis was the only factor associated with poor outcomes in the hereditary forms. In the family screening, 37.5% of relatives tested positive.
CONCLUSIONS: The genetics of pulmonary arterial hypertension in the Spanish population may differ from other populations, with a lower proportion of BMPR2 causative mutations. In our cohort, TBX4-related forms of pulmonary arterial hypertension showed a more benign course and late diagnosis was the only predictor of adverse outcomes in the hereditary forms of the disease.
Copyright © 2016 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  BMPR2; Cribado; Hereditary pulmonary arterial hypertension; Hipertensión arterial pulmonar heredable; Hipertensión arterial pulmonar idiopática; Idiopathic pulmonary arterial hypertension; KCNK3; Screening; TBX4

Mesh:

Substances:

Year:  2016        PMID: 27453251     DOI: 10.1016/j.rec.2016.03.029

Source DB:  PubMed          Journal:  Rev Esp Cardiol (Engl Ed)        ISSN: 1885-5857


  13 in total

Review 1.  The role of genetics in pulmonary arterial hypertension.

Authors:  Lijiang Ma; Wendy K Chung
Journal:  J Pathol       Date:  2016-11-29       Impact factor: 7.996

Review 2.  Genetics and Other Omics in Pediatric Pulmonary Arterial Hypertension.

Authors:  Carrie L Welch; Wendy K Chung
Journal:  Chest       Date:  2020-01-30       Impact factor: 9.410

Review 3.  Genes that drive the pathobiology of pediatric pulmonary arterial hypertension.

Authors:  Carrie L Welch; Eric D Austin; Wendy K Chung
Journal:  Pediatr Pulmonol       Date:  2020-01-09

4.  Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH.

Authors:  Na Zhu; Emilia M Swietlik; Carrie L Welch; Michael W Pauciulo; Nicholas W Morrell; Yufeng Shen; Stefan Gräf; William C Nichols; Wendy K Chung; Jacob J Hagen; Xueya Zhou; Yicheng Guo; Johannes Karten; Divya Pandya; Tobias Tilly; Katie A Lutz; Jennifer M Martin; Carmen M Treacy; Erika B Rosenzweig; Usha Krishnan; Anna W Coleman; Claudia Gonzaga-Jauregui; Allan Lawrie; Richard C Trembath; Martin R Wilkins
Journal:  Genome Med       Date:  2021-05-10       Impact factor: 15.266

5.  Clinical heterogeneity of Pulmonary Arterial Hypertension associated with variants in TBX4.

Authors:  Ignacio Hernandez-Gonzalez; Jair Tenorio; Julian Palomino-Doza; Amaya Martinez Meñaca; Rafael Morales Ruiz; Mauro Lago-Docampo; María Valverde Gomez; Javier Gomez Roman; Ana Belén Enguita Valls; Carmen Perez-Olivares; Diana Valverde; Joan Gil Carbonell; Elvira Garrido-Lestache Rodríguez-Monte; Maria Jesus Del Cerro; Pablo Lapunzina; Pilar Escribano-Subias
Journal:  PLoS One       Date:  2020-04-29       Impact factor: 3.240

6.  Gender differences in pulmonary arterial hypertension patients with BMPR2 mutation: a meta-analysis.

Authors:  Xiaoyue Ge; Tiantian Zhu; Xinyi Zhang; Ye Liu; Yonglong Wang; Weifang Zhang
Journal:  Respir Res       Date:  2020-02-06

Review 7.  The Biological Bases of Group 2 Pulmonary Hypertension.

Authors:  Ana I Fernández; Raquel Yotti; Ana González-Mansilla; Teresa Mombiela; Enrique Gutiérrez-Ibanes; Candelas Pérez Del Villar; Paula Navas-Tejedor; Christian Chazo; Pablo Martínez-Legazpi; Francisco Fernández-Avilés; Javier Bermejo
Journal:  Int J Mol Sci       Date:  2019-11-23       Impact factor: 5.923

8.  KCNK3 Mutation Causes Altered Immune Function in Pulmonary Arterial Hypertension Patients and Mouse Models.

Authors:  James D West; Eric D Austin; Elise M Rizzi; Ling Yan; Harikrishna Tanjore; Amber L Crabtree; Christy S Moore; Gladson Muthian; Erica J Carrier; David A Jacobson; Rizwan Hamid; Peggy L Kendall; Susan Majka; Anandharajan Rathinasabapathy
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

9.  Characterization and regulation of wild-type and mutant TASK-1 two pore domain potassium channels indicated in pulmonary arterial hypertension.

Authors:  Kevin P Cunningham; Robyn G Holden; Pilar M Escribano-Subias; Angel Cogolludo; Emma L Veale; Alistair Mathie
Journal:  J Physiol       Date:  2018-11-24       Impact factor: 5.182

Review 10.  TBX4 variants and pulmonary diseases: getting out of the 'Box'.

Authors:  Meindina G Haarman; Wilhelmina S Kerstjens-Frederikse; Rolf M F Berger
Journal:  Curr Opin Pulm Med       Date:  2020-05       Impact factor: 2.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.